不可切除结直肠癌肝转移一线系统治疗后总肿瘤体积缩减比的评估
本研究纳入240例初始不可切除的结直肠癌肝转移患者,基于CT或MRI三维重建评估一线系统治疗前后总肿瘤体积(TTV),分析TTV缩减比与转化结局及生存的关系。212例(88.3%)患者获得肿瘤退缩,中位TTV缩减比为86.0%。TTV缩减比>86.0%者5年总生存率和无进展生存率均优于0-86.0%组及<0组,TTV缩减比≤86.0%是转化失败及不良OS、PFS的独立因素。
要点
- TTV缩减比>86.0%者5年OS为64.4%,优于0-86.0%组的44.9%和<0组的23.5%(P<0.001)。
- TTV缩减比≤86.0%是转化失败的独立因素(OR 4.956,95%CI 2.654-9.253,P<0.001)。
- TTV缩减比≤86.0%是不良OS(HR 2.216,95%CI 1.332-3.688,P=0.002)和PFS(HR 2.023,95%CI 1.376-2.974,P<0.001)的独立因素。
核心结论
- TTV缩减比是初始不可切除结直肠癌肝转移患者一线系统治疗后转化结局和长期预后的有效指标。
研究设计与样本
- 研究纳入240例接受一线系统治疗的初始不可切除结直肠癌肝转移患者,依据CT或MRI图像使用三维重建系统评估基线及一线治疗结束时的TTV,采用Kaplan-Meier分析和Cox比例风险比评估生存。
关键影像表现/征象
- 212例(88.3%)患者获得肿瘤退缩,中位TTV缩减比为86.0%。
- TTV缩减比增大与转化成功结局逐渐升高相关。
诊断标准与关键数值
- TTV缩减比>86.0%组5年OS率为64.4%,0-86.0%组为44.9%,<0组为23.5%(P<0.001)。
- TTV缩减比>86.0%组5年PFS率为36.3%,0-86.0%组为28.2%,<0组为6.5%(P<0.001)。
- TTV缩减比≤86.0%是转化失败的独立因素(OR 4.956,95%CI 2.654-9.253,P<0.001)。
- TTV缩减比≤86.0%是不良OS的独立因素(HR 2.216,95%CI 1.332-3.688,P=0.002)。
- TTV缩减比≤86.0%是不良PFS的独立因素(HR 2.023,95%CI 1.376-2.974,P<0.001)。
临床应用与阅片要点
- 基于CT或MRI图像使用三维重建系统测量基线及一线治疗结束时的TTV,计算TTV缩减比。
- TTV缩减比>86.0%与更好的转化结局及长期生存相关,TTV缩减比≤86.0%提示转化失败及不良预后风险升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Total tumor volume (TTV) may play an essential role in the estimation of tumor burden. This study is aimed to investigate the clinical value of the reduction ratio of TTV as a valuable indicator of clinical outcomes in patients with colorectal liver metastases (CRLM).
METHODS: A total of 240 initially unresectable CRLM patients who underwent first-line systemic treatment were enrolled in this study. TTV at baseline and at the end of first-line treatment were assessed using a three-dimensional reconstruction system according to CT or MRI images. Survival was evaluated using Kaplan-Meier analysis and compared using Cox proportional hazard ratios (HR).
RESULTS: A total of 212 (88.3%) patients achieved tumor regression with a median reduction ratio of TTV of 86.0%. An increasing reduction ratio of TTV was associated with a gradually ascending successful conversion outcome. Patients with a reduction ratio >86.0% had better survival than those with a reduction ratio 0-86.0% or <0 (5-year overall survival (OS) rates, 64.4% vs. 44.9% vs. 23.5%, P < 0.001; 5-year progression-free survival (PFS) rates, 36.3% vs. 28.2% vs. 6.5%, P < 0.001). Multivariate analysis indicated that the reduction ratio of TTV ≤ 86.0% (OR [95%CI]: 4.956 [2.654-9.253], P < 0.001) was an independent factor for conversion failure outcome. Cox analyses revealed that the reduction ratio of TTV ≤ 86.0% was an independent factor for both unfavorable OS (HR [95%CI]: 2.216 [1.332-3.688], P = 0.002) and PFS (HR [95%CI]: 2.023 [1.376-2.974], P < 0.001).
CONCLUSIONS: The reduction ratio of TTV was an effective indicator for conversion outcome and long-term prognosis in patients with initially unresectable CRLM after first-line systemic treatment.
引用
- He J, Li W, Zhou J, et al. Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment. Eur J Radiol. 2023. PMID: 37437437. doi:10.1016/j.ejrad.2023.110950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。